Posts tagged Phase 1/2
Titan Pharma implant IND cleared for Parkinson’s study

The FDA has cleared an IND application by Titan Pharmaceuticals (NASDAQ:TTNP) for its ropinirole implant intended to treat the signs and symptoms of Parkinson's disease.

Read More
Ladenburg starts Catalyst at buy

Ladenburg Thalmann initiated coverage of Catalyst Biosciences (NASDAQ:CBIO) with a ‘buy” rating and $11.00 price target. The stock closed at $4.17 on June 5.

Read More
BioTime forms new AgeX unit on human aging

BioTime (NYSE MKT:BTX) has created AgeX Therapeutics, which will consolidate certain BioTime subsidiaries and programs in the field of interventional gerontology.

Read More
Roth starts Fate Therapeutics at buy

Roth Capital Partners has launched coverage of Fate Therapeutics (NASDAQ:FATE) with a “buy” rating and a target price of $8. The stock closed at $3.18 on Wednesday.

Analyst Mark Breidenbach writes that the company's lead asset, ProTmune, could address a serious unmet medical need in patients requiring hematopoietic transplants (HSCTs), and “we expect to see early clinical data by the end of 2016.”

Read More
Roth starts Actinium Pharma at buy

Roth Capital Partners initiated coverage of Actinium Pharmaceuticals (NYSE MKT:ATNM) with a “buy” rating and $5 price target. The stock closed at $1.66 on Wednesday.

“We believe it is an opportune time to explore the investment case of Actinium based on the late-stage nature of the lead asset, addressing unmet medical needs, clinical data in hand, and a broad set of upcoming catalysts,” writes analyst Joseph Pantginis.

Read More
ARIAD Pharma initiates Phase 1/2 trial in NSCLC

ARIAD Pharmaceuticals (NASDAQ:ARIA) has initiated a Phase 1/2 clinical trial of AP32788, an investigational tyrosine kinase inhibitor (TKI) designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in EGFR or HER2.

AP32788 targets tumors driven by EGFR or HER2 kinases and was designed to achieve selective inhibition of these kinases with exon 20 mutations. There are currently no approved targeted treatment options available for the approximately 4% to 9% of EGFR-mutated lung tumors with exon 20 insertion mutations in NSCLC patients.

Read More